Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/24938
Başlık: Single-agent irinotecan as second-line treatment for advanced gastric cancer
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Medikal Onkoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.
0000-0002-9732-5340
0000-0003-2501-3097
0000-0002-3208-6211
Kanat, Özkan
Evrensel, Türkkan
Manavoğlu, Osman
Demiray, Mutlu
Kurt, Ender
Gönüllü, Güzin
Kıyıcı, Murat
Arslan, Murat
AAJ-1027-2021
M-8060-2019
55881548500
6603942124
6602587152
6603631569
7006207332
6506410014
6507627491
57197925370
Anahtar kelimeler: Oncology
Gastric cancer
Irinotecan
Second-line chemotherapy
Supportive care
Phase-II
Methotrexate
Carboplatin
Paclitaxel
Cisplatin
Yayın Tarihi: 2003
Yayıncı: Sage Publications
Atıf: Kanat, O. vd. (2003). “Single-agent irinotecan as second-line treatment for advanced gastric cancer”. Tumori Journal, 89(4), 405-407.
Özet: Aim. To investigate the activity and toxicity of irinotecan (CPT-11) as a single agent in patients with advanced gastric cancer after failure of previous 5-fluorouracil-based combination chemotherapy. Patients and methods: Sixteen patients with advanced gastric received CPT-11, 350 mg/m2 every 21 days. The median age of the patients was 54.6 years; ECOG performance status was 0-1 in 14 patients and 2 in 2 patients. Dominant metastatic sites included liver, lung, lymph nodes and peritoneum. Results: No complete response was observed. Two patients (12.5%) achieved a partial response to treatment. One patient (6.25%) had a minor response. Ten patients (62.5%) had progressive disease on therapy, and 3 patients (18.75%) had stable disease. The median survival of all 16 patients was 5 months. Grade 3 neutropenia was observed in 3 patients (18.75%), grade 4 thrombocytopenia in 1 patient (6.25%), and grade 3 anemia in 1 patient (6.25%). Three patients (18.75%) suffered from grade 3 diarrhea. Conclusions: CPT-11 is moderately active and a well-tolerated regimen for selected advanced gastric cancer patients who experience disease progression after receiving first-line treatment.
URI: https://doi.org/0.1177/030089160308900411
https://journals.sagepub.com/doi/abs/10.1177/030089160308900411
http://hdl.handle.net/11452/24938
ISSN: 0300-8916
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.